US 9,808,477 B2
Use of nobiletin in cancer treatment
Wen-zhe Ma, Macau (CN); Sen-ling Feng, Macau (CN); Xiao-jun Yao, Macau (DJ); Zhong-wen Yuan, Macau (CN); Liang Liu, Macau (CN); and Ying Xie, Macau (CN)
Assigned to Macau University of Science and Technology, Macau (CN)
Filed by Macau University of Science and Technology, Macau (CN)
Filed on Sep. 9, 2015, as Appl. No. 14/848,358.
Claims priority of provisional application 62/198,137, filed on Jul. 29, 2015.
Prior Publication US 2017/0027901 A1, Feb. 2, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 31/337 (2006.01); A61K 45/06 (2006.01); A61K 31/704 (2006.01)
CPC A61K 31/704 (2013.01) [A61K 31/337 (2013.01); A61K 31/352 (2013.01); A61K 45/06 (2013.01)] 8 Claims
1. A method of treating multidrug resistance cancer, comprising:
administering a pharmaceutically effective amount of a citrus methoxyflavone and a chemotherapeutic drug to a subject in need thereof,
wherein the citrus methoxyflavone is nobiletin, the chemotherapeutic drug is paclitaxel, and the multidrug resistance cancer is paclitaxel-resistant ovarian cancer;
wherein the paclitaxel and the nobiletin are administered to the subject in a molar ratio of 0.94:0.5 to 0.94:9 to treat the paclitaxel-resistant ovarian cancer.